Linked In – Author Duane Boise
Washington, D.C. February 18, 2026
The regulatory dispute involving MMJ BioPharma Cultivation and the Drug Enforcement Administration has evolved beyond a single bulk manufacturing registration application.
It now stands at the intersection of three consequential developments:
- Procedural irregularities within the DEA’s Administrative Law Judge (ALJ) process
- A formal constitutional reassessment of ALJ removal protections by the Department of Justice
- The anticipated federal transition of marijuana to Schedule III
Importantly, MMJ’s application has not been denied. The matter remains pending before the DEA Administrator for final decision. That procedural posture is central to understanding the significance of this moment.
The DEA ALJ Process — and What Makes This Case Unusual
Under the Controlled Substances Act, when the DEA proposes to deny or revoke a registration, the matter is assigned to an Administrative Law Judge. The ALJ conducts proceedings that resemble a trial, receives evidence, evaluates testimony, and issues a recommended decision. However, that recommendation is not final. Parties may file exceptions, and the complete record is forwarded to the DEA Administrator, who retains sole authority to issue final agency action.
In MMJ’s case, the administrative trajectory has been marked by irregular circumstances. A recommended decision was issued without the development of a fully completed evidentiary record typically associated with a merits hearing. In addition, the matter experienced turnover among presiding administrative judges before final agency action occurred. MMJ formally preserved its procedural and constitutional objections through exceptions.
The case now rests before the Administrator. No final decision has been entered.
The DOJ’s Notice of Change in Position
Compounding the procedural complexity, the Department of Justice filed a formal Notice of Change in Position in the United States District Court for the District of Rhode Island in MMJ BioPharma Cultivation Inc. v. Bondi et al., Civil Action No. 1:24-cv-127-WES-PAS.
In that filing, submitted under Pamela Bondi in her official capacity as U.S. Attorney General, the government informed the court that:
- The Acting Solicitor General has determined that the multiple layers of removal protections for ALJs under 5 U.S.C. § 7521 do not comport with Article II’s separation-of-powers requirements.
- The Department of Justice will no longer defend those removal protections in litigation.
At the same time, the government maintained its position that MMJ had not demonstrated concrete harm under the Supreme Court’s decision in Collins v. Yellen, and therefore argued dismissal remains appropriate.
This is a significant development. The executive branch has effectively acknowledged constitutional vulnerability in the structural insulation of ALJs — including those within the DEA.
The Broader Constitutional Context
The DOJ’s position aligns with recent Supreme Court rulings that have narrowed protections for insulated agency adjudicators, including:
- Seila Law LLC v. CFPB
- Collins v. Yellen
- Axon Enterprise, Inc. v. FTC
- SEC v. Jarkesy
These decisions collectively signal heightened judicial scrutiny of executive agencies that exercise adjudicative authority through insulated in-house tribunals.
While the DEA ALJ system remains operational, its constitutional footing is no longer unquestioned.
Why This Matters in the Context of Schedule III
The potential rescheduling of marijuana to Schedule III represents a structural shift in federal cannabis governance.
Under Schedule I, the DEA operates within a prohibition-centered framework.
Under Schedule III, the agency transitions toward managing a regulated pharmaceutical ecosystem within a controlled distribution system. In such an environment:
- Registration decisions become economically consequential.
- Pharmaceutical-grade research and manufacturing normalize.
- Institutional capital engagement increases.
- Litigation scrutiny intensifies around agency consistency and transparency.
As the federal government recalibrates cannabis policy, the integrity and constitutional defensibility of the DEA’s adjudicative system become more, not less, important.
Issuing consequential registration decisions while the ALJ removal structure faces constitutional reassessment presents institutional risk.
MMJ’s Strategic Position at an Inflection Point
MMJ occupies a distinctive posture in this transition:
- Its application remains pending — not denied.
- Its development model is pharmaceutical-focused, not retail-oriented.
- It is aligned with FDA clinical objectives, including orphan disease pathways.
- It has preserved structural constitutional challenges within the administrative and judicial record.
This places MMJ at a regulatory inflection point as federal cannabis policy moves toward pharmaceutical normalization.
The Administrator’s eventual decision will occur against the backdrop of:
- A live constitutional reassessment of ALJ protections
- Ongoing federal litigation
- The broader policy shift toward Schedule III
A Prelude to Federal Governance Reform
This moment does not predetermine the outcome of MMJ’s application.
But it reflects a broader recalibration:
- Reassessment of agency adjudicative insulation
- Reexamination of cannabis scheduling
- Convergence between pharmaceutical regulation and cannabinoid development
As marijuana potentially transitions from Schedule I to Schedule III, the structure, transparency, and constitutional defensibility of DEA decision-making will shape the next phase of federal cannabis governance.
MMJ’s case is not merely an individual registration dispute.
It has become an early test of how federal regulatory authority will function in a post-Schedule I framework — where science, separation of powers, and commercial normalization increasingly intersect.
